Role of mast cells and bioactive peptides in the pathogenesis of systemic sclerosis and pulmonary hypertension

Role of mast cells and bioactive peptides in the pathogenesis of systemic sclerosis and pulmonary hypertension - Role of mast cells in the pathogenesis of systemic sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026638

Enrollment

230

Registered

2017-03-24

Start date

2014-04-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic sclerosis/pulmonary hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with systemic sclerosis, MCTD, and other collagen vascular diseases (complicated with pulmonary hypertension) in Kyushu University Hospital

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Assessment of serum levels of ET-1, AT II, VIP, Hsp70, Billycan, HMGB1, and IL-33 in patients with systemic sclerosis and pulmonary hypertension	—

Countries

Japan

Contacts

Public ContactYusuke Kashiwado

Kyushu University Graduate School of Medicine Department of Medicine and Biosystemic Sciences

kashiwa@intmed1.med.kyushu-u.ac.jp092-642-5233

Outcome results